{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T06:50:01Z","timestamp":1793083801404,"version":"4.5.0"},"reference-count":195,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,6,30]],"date-time":"2027-06-30T00:00:00Z","timestamp":1814313600000},"content-version":"am","delay-in-days":272,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["RR210067"],"award-info":[{"award-number":["RR210067"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA288403"],"award-info":[{"award-number":["R01CA288403"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["1R37CA251318-01"],"award-info":[{"award-number":["1R37CA251318-01"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA278911"],"award-info":[{"award-number":["R01CA278911"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA258477-01"],"award-info":[{"award-number":["R01CA258477-01"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["1R01CA248111-01A1"],"award-info":[{"award-number":["1R01CA248111-01A1"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.canlet.2026.218699","type":"journal-article","created":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T14:19:17Z","timestamp":1782656357000},"page":"218699","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Multi-dimensional orchestration of binders for improved CAR-T immunotherapy"],"prefix":"10.1016","volume":"657","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3930-9024","authenticated-orcid":false,"given":"Chaoyang","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiwu","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Jing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0077-0040","authenticated-orcid":false,"given":"Yong","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2026.218699_bib1","first-page":"372","article-title":"Mechanisms of resistance to CAR T cell therapy","volume":"16","author":"Shah","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.canlet.2026.218699_bib2","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","article-title":"Long-term outcomes following CAR T cell therapy: what we know so far","volume":"20","author":"Cappell","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.canlet.2026.218699_bib3","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1016\/j.ymthe.2023.03.020","article-title":"Dual targeting of CD19 and CD22 against B-ALL using a novel high-sensitivity aCD22 CAR","volume":"31","author":"Kokalaki","year":"2023","journal-title":"Mol. Ther."},{"key":"10.1016\/j.canlet.2026.218699_bib4","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1182\/blood-2013-03-490565","article-title":"Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma","volume":"122","author":"Linette","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2026.218699_bib5","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1016\/j.ymthe.2018.05.003","article-title":"Dominant-negative TGF-\u03b2 receptor enhances PSMA-targeted human CAR T cell proliferation and augments prostate cancer eradication","volume":"26","author":"Kloss","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.canlet.2026.218699_bib6","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1038\/s41591-018-0146-z","article-title":"Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia","volume":"24","author":"Orlando","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2026.218699_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.216871","article-title":"The dilemmas and possible solutions for CAR-T cell therapy application in solid tumors","volume":"591","author":"Wang","year":"2024","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2026.218699_bib8","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/s41576-021-00329-9","article-title":"Genetic engineering of T cells for immunotherapy","volume":"22","author":"Ellis","year":"2021","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.canlet.2026.218699_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2025.217771","article-title":"The mechanisms and countermeasures for CAR-T cell expansion and persistence deficiency","volume":"626","author":"Bao","year":"2025","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2026.218699_bib10","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.coi.2009.02.009","article-title":"The promise and potential pitfalls of chimeric antigen receptors","volume":"21","author":"Sadelain","year":"2009","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.canlet.2026.218699_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2025.217541","article-title":"The development and potent antitumor efficacy of CD44\/CD133 dual-targeting IL7R\u03b1-armored CAR-T cells against glioblastoma","volume":"614","author":"Zhai","year":"2025","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2026.218699_bib12","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1016\/j.ccell.2025.05.006","article-title":"Mutant KRAS peptide targeted CAR-T cells engineered for cancer therapy","volume":"43","author":"Benton","year":"2025","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2026.218699_bib13","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1007\/s00109-025-02585-2","article-title":"Targeting mutated KRAS by HLA-A\u221702:01 restricted anti-KRAS TCR-mimic CAR and bispecific T cell engager","volume":"103","author":"Ebrahimi","year":"2025","journal-title":"J. Mol. Med. (Berl.)"},{"key":"10.1016\/j.canlet.2026.218699_bib14","doi-asserted-by":"crossref","first-page":"5333","DOI":"10.1038\/s41467-022-32811-1","article-title":"Therapeutic high affinity T cell receptor targeting a KRAS(G12D) cancer neoantigen","volume":"13","author":"Poole","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2026.218699_bib15","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1609279","article-title":"T-Cell transfer therapy targeting mutant KRAS in cancer","volume":"375","author":"Tran","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2026.218699_bib16","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/imr.12772","article-title":"T cell receptor-based cancer immunotherapy: emerging efficacy and pathways of resistance","volume":"290","author":"Chandran","year":"2019","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.canlet.2026.218699_bib17","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.smim.2016.02.001","article-title":"Role of memory T cell subsets for adoptive immunotherapy","volume":"28","author":"Busch","year":"2016","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.canlet.2026.218699_bib18","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41586-022-04585-5","article-title":"CAR T cell killing requires the IFN\u03b3R pathway in solid but not liquid tumours","volume":"604","author":"Larson","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2026.218699_bib19","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1053\/j.gastro.2020.02.011","article-title":"Persistent polyfunctional chimeric antigen receptor T cells that target glypican 3 eliminate orthotopic hepatocellular carcinomas in mice","volume":"158","author":"Li","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.canlet.2026.218699_bib20","doi-asserted-by":"crossref","DOI":"10.3390\/antib13020045","article-title":"Antibody recognition of human epidermal growth factor Receptor-2 (HER2) juxtamembrane domain enhances anti-tumor response of chimeric antigen receptor (CAR)-T cells","volume":"13","author":"Zhou","year":"2024","journal-title":"Antibodies"},{"key":"10.1016\/j.canlet.2026.218699_bib21","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.it.2015.06.004","article-title":"Engineering CAR-T cells: design concepts","volume":"36","author":"Srivastava","year":"2015","journal-title":"Trends Immunol."},{"key":"10.1016\/j.canlet.2026.218699_bib22","doi-asserted-by":"crossref","first-page":"4295","DOI":"10.1182\/blood-2012-07-442251","article-title":"The large ectodomains of CD45 and CD148 regulate their segregation from and inhibition of ligated T-cell receptor","volume":"121","author":"Cordoba","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2026.218699_bib23","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/nm.4441","article-title":"CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy","volume":"24","author":"Fry","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2026.218699_bib24","doi-asserted-by":"crossref","first-page":"3153","DOI":"10.1158\/1078-0432.CCR-13-0330","article-title":"Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells","volume":"19","author":"Hudecek","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2026.218699_bib25","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1038\/s41591-019-0549-5","article-title":"Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR","volume":"25","author":"Ghorashian","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2026.218699_bib26","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1158\/2326-6066.CIR-14-0163","article-title":"Safety of targeting ROR1 in primates with chimeric antigen receptor-modified T cells","volume":"3","author":"Berger","year":"2015","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.canlet.2026.218699_bib27","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.ymthe.2018.01.020","article-title":"Immunological synapse predicts effectiveness of chimeric antigen receptor cells","volume":"26","author":"Xiong","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.canlet.2026.218699_bib28","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S0092-8674(02)01079-6","article-title":"Matrilysin shedding of syndecan-1 regulates chemokine mobilization and transepithelial efflux of neutrophils in acute lung injury","volume":"111","author":"Li","year":"2002","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2026.218699_bib29","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1083\/jcb.153.5.893","article-title":"Membrane-type 1 matrix metalloproteinase cleaves CD44 and promotes cell migration","volume":"153","author":"Kajita","year":"2001","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.canlet.2026.218699_bib30","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001875","article-title":"Shed antigen-induced blocking effect on CAR-T cells targeting Glypican-3 in hepatocellular Carcinoma","volume":"9","author":"Sun","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.canlet.2026.218699_bib31","article-title":"Tumor resistance to anti-mesothelin CAR-T cells caused by binding to shed mesothelin is overcome by targeting a juxtamembrane epitope","volume":"121","author":"Liu","year":"2024","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.canlet.2026.218699_bib32","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-012822","article-title":"Tandem CAR-T cells targeting mesothelin and MUC16 overcome tumor heterogeneity by targeting one antigen at a time","volume":"13","author":"Salas-Benito","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.canlet.2026.218699_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2022.215668","article-title":"Tumor-derived extracellular vesicles induce invalid cytokine release and exhaustion of CD19 CAR-T cells","volume":"536","author":"Zhu","year":"2022","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2026.218699_bib34","article-title":"Highly active CAR T cells that bind to a juxtamembrane region of mesothelin and are not blocked by shed mesothelin","volume":"119","author":"Liu","year":"2022","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.canlet.2026.218699_bib35","article-title":"MUC1 and MUC16: critical for immune modulation in cancer therapeutics","volume":"15","author":"Chen","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.canlet.2026.218699_bib36","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0065-230X(08)60798-8","article-title":"Shedding of human tumor-associated antigens in vitro and in vivo","volume":"49","author":"Herlyn","year":"1987","journal-title":"Adv. Cancer Res."},{"key":"10.1016\/j.canlet.2026.218699_bib37","article-title":"A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma","volume":"9","author":"O'Rourke","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.canlet.2026.218699_bib38","doi-asserted-by":"crossref","DOI":"10.1242\/jcs.247189","article-title":"EGFRvIII uses intrinsic and extrinsic mechanisms to reduce glioma adhesion and increase migration","volume":"133","author":"Banisadr","year":"2020","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.canlet.2026.218699_bib39","doi-asserted-by":"crossref","first-page":"3596","DOI":"10.1158\/0008-5472.CAN-15-0159","article-title":"Affinity-Tuned ErbB2 or EGFR chimeric antigen receptor T cells exhibit an increased therapeutic index against tumors in mice","volume":"75","author":"Liu","year":"2015","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2026.218699_bib40","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.136012","article-title":"A rational mouse model to detect on-target, off-tumor CAR T cell toxicity","volume":"5","author":"Castellarin","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.canlet.2026.218699_bib41","doi-asserted-by":"crossref","first-page":"3505","DOI":"10.1158\/0008-5472.CAN-15-0139","article-title":"Tuning sensitivity of CAR to EGFR density limits recognition of normal tissue while maintaining potent antitumor activity","volume":"75","author":"Caruso","year":"2015","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2026.218699_bib42","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/mt.2010.24","article-title":"Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2","volume":"18","author":"Morgan","year":"2010","journal-title":"Mol. Ther."},{"key":"10.1016\/j.canlet.2026.218699_bib43","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1016\/j.ymthe.2017.06.008","article-title":"Tumor antigen and receptor densities regulate efficacy of a chimeric antigen receptor targeting anaplastic lymphoma kinase","volume":"25","author":"Walker","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.canlet.2026.218699_bib44","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1032403","article-title":"The affinity of antigen-binding domain on the antitumor efficacy of CAR T cells: moderate is better","volume":"13","author":"Mao","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.canlet.2026.218699_bib45","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.186268","article-title":"Affinity-tuned mesothelin CAR T cells demonstrate enhanced targeting specificity and reduced off-tumor toxicity","volume":"9","author":"Yang","year":"2024","journal-title":"JCI Insight"},{"key":"10.1016\/j.canlet.2026.218699_bib46","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1158\/2159-8290.CD-19-0945","article-title":"Tuning the antigen density requirement for CAR T-cell activity","volume":"10","author":"Majzner","year":"2020","journal-title":"Cancer Discov."},{"key":"10.1016\/j.canlet.2026.218699_bib47","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.adf1426","article-title":"CD19 CAR antigen engagement mechanisms and affinity tuning","volume":"8","author":"He","year":"2023","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.canlet.2026.218699_bib48","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008566","article-title":"Systemically administered low-affinity HER2 CAR T cells mediate antitumor efficacy without toxicity","volume":"12","author":"Shabaneh","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.canlet.2026.218699_bib49","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1016\/j.ymthe.2017.04.017","article-title":"Balance of Anti-CD123 chimeric antigen receptor binding affinity and density for the targeting of acute myeloid leukemia","volume":"25","author":"Arcangeli","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.canlet.2026.218699_bib50","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/s41422-023-00789-0","article-title":"Tuning charge density of chimeric antigen receptor optimizes tonic signaling and CAR-T cell fitness","volume":"33","author":"Chen","year":"2023","journal-title":"Cell Res."},{"key":"10.1016\/j.canlet.2026.218699_bib51","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1111\/imr.13232","article-title":"Charging CAR by electrostatic power","volume":"320","author":"Wang","year":"2023","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.canlet.2026.218699_bib52","doi-asserted-by":"crossref","first-page":"4732","DOI":"10.1038\/s41467-023-40303-z","article-title":"Complementarity-determining region clustering may cause CAR-T cell dysfunction","volume":"14","author":"Sar\u00e9n","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2026.218699_bib53","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/s41422-024-00936-1","article-title":"CAR-Toner: an AI-driven approach for CAR tonic signaling prediction and optimization","volume":"34","author":"Qiu","year":"2024","journal-title":"Cell Res."},{"key":"10.1016\/j.canlet.2026.218699_bib54","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1016\/j.ymthe.2017.05.012","article-title":"CAR T cells administered in combination with lymphodepletion and PD-1 inhibition to patients with neuroblastoma","volume":"25","author":"Heczey","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.canlet.2026.218699_bib55","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2219086120","article-title":"Tonic-signaling chimeric antigen receptors drive human regulatory T cell exhaustion","volume":"120","author":"Lamarche","year":"2023","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.canlet.2026.218699_bib56","doi-asserted-by":"crossref","first-page":"16017","DOI":"10.1038\/mtm.2016.17","article-title":"Production of lentiviral vectors","volume":"3","author":"Merten","year":"2016","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.canlet.2026.218699_bib57","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.tibtech.2014.03.001","article-title":"Nanobody-based products as research and diagnostic tools","volume":"32","author":"De Meyer","year":"2014","journal-title":"Trends Biotechnol."},{"key":"10.1016\/j.canlet.2026.218699_bib58","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S0022-2836(03)00896-9","article-title":"Designing repeat proteins: well-expressed, soluble and stable proteins from combinatorial libraries of consensus ankyrin repeat proteins","volume":"332","author":"Binz","year":"2003","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.canlet.2026.218699_bib59","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1182\/blood.2020006770","article-title":"Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies","volume":"137","author":"Gauthier","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2026.218699_bib60","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1158\/1078-0432.CCR-24-2172","article-title":"Phase I study of ROR1-Specific CAR-T cells in advanced hematopoietic and epithelial malignancies","volume":"31","author":"Jaeger-Ruckstuhl","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2026.218699_bib61","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI85309","article-title":"CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients","volume":"126","author":"Turtle","year":"2016","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.canlet.2026.218699_bib62","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2112006119","article-title":"Engineered IL13 variants direct specificity of IL13R\u03b12-targeted CAR T cell therapy","volume":"119","author":"Stern","year":"2022","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.canlet.2026.218699_bib63","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21239163","article-title":"Identification of potent CD19 scFv for CAR T cells through scFv screening with NK\/T-Cell line","volume":"21","author":"Kang","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.canlet.2026.218699_bib64","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241310891","article-title":"Recombinant human CD19 in CHO-K1 cells: glycosylation patterns as a quality attribute of high yield processes","volume":"24","author":"Billerhart","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.canlet.2026.218699_bib65","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric antigen receptor-modified T cells for acute lymphoid leukemia","volume":"368","author":"Grupp","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2026.218699_bib66","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/s41573-019-0051-2","article-title":"'Off-the-shelf' allogeneic CAR T cells: development and challenges","volume":"19","author":"Depil","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.canlet.2026.218699_bib67","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-Cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2026.218699_bib68","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-Cell therapy in refractory large B-Cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2026.218699_bib69","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/S0161-5890(97)00144-2","article-title":"Construction and characterisation of a functional CD19 specific single chain Fv fragment for immunotherapy of B lineage leukaemia and lymphoma","volume":"34","author":"Nicholson","year":"1997","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.canlet.2026.218699_bib70","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2406526","article-title":"Obecabtagene autoleucel in adults with B-Cell acute lymphoblastic leukemia","volume":"391","author":"Roddie","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2026.218699_bib71","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2026.218699_bib72","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.canlet.2026.218699_bib73","doi-asserted-by":"crossref","first-page":"2890","DOI":"10.1182\/blood.2020008936","article-title":"A phase 1 study of a novel fully human BCMA-targeting CAR (CT103A) in patients with relapsed\/refractory multiple myeloma","volume":"137","author":"Wang","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2026.218699_bib74","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1146\/annurev-biochem-063011-092449","article-title":"Nanobodies: natural single-domain antibodies","volume":"82","author":"Muyldermans","year":"2013","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.canlet.2026.218699_bib75","doi-asserted-by":"crossref","first-page":"4586","DOI":"10.1073\/pnas.0505379103","article-title":"Molecular basis for the preferential cleft recognition by dromedary heavy-chain antibodies","volume":"103","author":"De Genst","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.canlet.2026.218699_bib76","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/nature18636","article-title":"Allosteric nanobodies reveal the dynamic range and diverse mechanisms of G-protein-coupled receptor activation","volume":"535","author":"Staus","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2026.218699_bib189","doi-asserted-by":"crossref","first-page":"e5084","DOI":"10.1002\/pro.5084","article-title":"Thermostability and binding properties of single-chained Fv fragments derived from therapeutic antibodies","volume":"33","author":"Tadokoro","year":"2024","journal-title":"Protein Sci."},{"key":"10.1016\/j.canlet.2026.218699_bib190","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/protein\/gzv002","article-title":"Structural and dynamic properties that govern the stability of an engineered fibronectin type III domain","volume":"28","author":"Porebski","year":"2015","journal-title":"Protein Eng. Des. Sel."},{"key":"10.1016\/j.canlet.2026.218699_bib191","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/nbt962","article-title":"High-affinity binders selected from designed ankyrin repeat protein libraries","volume":"22","author":"Binz","year":"2004","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.canlet.2026.218699_bib192","doi-asserted-by":"crossref","DOI":"10.3390\/molecules26102874","article-title":"Stability enhancement of a dimeric HER2-Specific affibody molecule through sortase A-Catalyzed head-to-tail cyclization","volume":"26","author":"Westerlund","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.canlet.2026.218699_bib193","doi-asserted-by":"crossref","first-page":"15486","DOI":"10.1073\/pnas.2136623100","article-title":"Ultrafast folding of alpha3D: a de novo designed three-helix bundle protein","volume":"100","author":"Zhu","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.canlet.2026.218699_bib113","doi-asserted-by":"crossref","first-page":"ra114","DOI":"10.1126\/scisignal.aab2677","article-title":"Instructive roles for cytokine-receptor binding parameters in determining signaling and functional potency","volume":"8","author":"Moraga","year":"2015","journal-title":"Sci. Signal."},{"key":"10.1016\/j.canlet.2026.218699_bib114","doi-asserted-by":"crossref","first-page":"16727","DOI":"10.1074\/jbc.M312316200","article-title":"Engineering an APRIL-specific B cell maturation antigen","volume":"279","author":"Patel","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.canlet.2026.218699_bib115","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1182\/blood-2017-05-781351","article-title":"An APRIL-based chimeric antigen receptor for dual targeting of BCMA and TACI in multiple myeloma","volume":"131","author":"Lee","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2026.218699_bib194","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1080\/02656730802149570","article-title":"Temperature sensitive peptides: engineering hyperthermia-directed therapeutics","volume":"24","author":"Mackay","year":"2008","journal-title":"Int. J. Hyperther."},{"key":"10.1016\/j.canlet.2026.218699_bib195","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1126\/science.adv3813","article-title":"De novo design and structure of a peptide-centric TCR mimic binding module","volume":"389","author":"Householder","year":"2025","journal-title":"Science"},{"key":"10.1016\/j.canlet.2026.218699_bib151","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1038\/s41586-023-06415-8","article-title":"De novo design of protein structure and function with RFdiffusion","volume":"620","author":"Watson","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2026.218699_bib77","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-Cell therapy bb2121 in relapsed or refractory multiple myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2026.218699_bib78","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-006699","article-title":"Limited efficacy of APRIL CAR in patients with multiple myeloma indicate challenges in the use of natural ligands for CAR T-cell therapy","volume":"11","author":"Lee","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.canlet.2026.218699_bib79","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2025.2560893","article-title":"Exploring the nanobody patent landscape: a focus on BCMA sequences and structural analysis","volume":"17","author":"Xu","year":"2025","journal-title":"mAbs"},{"key":"10.1016\/j.canlet.2026.218699_bib80","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1158\/2643-3230.BCD-20-0020","article-title":"Defining an optimal dual-targeted CAR T-cell therapy approach simultaneously targeting BCMA and GPRC5D to prevent BCMA escape-driven relapse in multiple myeloma","volume":"1","author":"Fern\u00e1ndez de Larrea","year":"2020","journal-title":"Blood Cancer Discov."},{"key":"10.1016\/j.canlet.2026.218699_bib81","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2025.218235","article-title":"Anti-BCMA-CAR-IL15 natural killer cells prevent multiple myeloma growth in the bone marrow but allow subsequent emergence of extramedullary disease","volume":"639","author":"Kaczmarek","year":"2026","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2026.218699_bib82","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1038\/nature02740","article-title":"Somatic diversification of variable lymphocyte receptors in the agnathan sea lamprey","volume":"430","author":"Pancer","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2026.218699_bib83","doi-asserted-by":"crossref","first-page":"17408","DOI":"10.1074\/jbc.M112.435289","article-title":"Atypical antigen recognition mode of a shark immunoglobulin new antigen receptor (IgNAR) variable domain characterized by humanization and structural analysis","volume":"288","author":"Kovalenko","year":"2013","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.canlet.2026.218699_bib84","doi-asserted-by":"crossref","first-page":"12891","DOI":"10.1073\/pnas.0904443106","article-title":"High-affinity lamprey VLRA and VLRB monoclonal antibodies","volume":"106","author":"Tasumi","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.canlet.2026.218699_bib85","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.omto.2022.02.015","article-title":"A novel PD-L1-targeted shark V(NAR) single-domain-based CAR-T cell strategy for treating breast cancer and liver cancer","volume":"24","author":"Li","year":"2022","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.canlet.2026.218699_bib86","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1407898","article-title":"Development of chimeric antigen receptors targeting T-cell malignancies using two structurally different anti-CD5 antigen binding domains in NK and CRISPR-edited T cell lines","volume":"7","author":"Raikar","year":"2018","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.canlet.2026.218699_bib87","doi-asserted-by":"crossref","first-page":"16026","DOI":"10.1038\/mto.2016.26","article-title":"Genetic engineering of chimeric antigen receptors using lamprey derived variable lymphocyte receptors","volume":"3","author":"Moot","year":"2016","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.canlet.2026.218699_bib88","doi-asserted-by":"crossref","first-page":"8383","DOI":"10.1038\/s41598-018-26560-9","article-title":"Engineered membrane protein antigens successfully induce antibodies against extracellular regions of claudin-5","volume":"8","author":"Hashimoto","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.canlet.2026.218699_bib89","article-title":"Epitope-directed antibody selection by site-specific photocrosslinking","volume":"6","author":"Chen","year":"2020","journal-title":"Sci. Adv."},{"key":"10.1016\/j.canlet.2026.218699_bib90","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1021\/acscentsci.3c00265","article-title":"Epitope-directed antibody elicitation by genetically encoded chemical cross-linking reactivity in the antigen","volume":"9","author":"Zhu","year":"2023","journal-title":"ACS Cent. Sci."},{"key":"10.1016\/j.canlet.2026.218699_bib91","doi-asserted-by":"crossref","first-page":"7624","DOI":"10.1073\/pnas.1817147116","article-title":"Nanobody-based CAR T cells that target the tumor microenvironment inhibit the growth of solid tumors in immunocompetent mice","volume":"116","author":"Xie","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.canlet.2026.218699_bib92","doi-asserted-by":"crossref","DOI":"10.1016\/j.trim.2022.101538","article-title":"Nanobody-based anti-CD22-chimeric antigen receptor T cell immunotherapy exhibits improved remission against B-cell acute lymphoblastic leukemia","volume":"71","author":"Zhang","year":"2022","journal-title":"Transpl. Immunol."},{"key":"10.1016\/j.canlet.2026.218699_bib93","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1038\/s41596-020-0304-x","article-title":"Generation of synthetic nanobodies against delicate proteins","volume":"15","author":"Zimmermann","year":"2020","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.canlet.2026.218699_bib94","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.34317","article-title":"Synthetic single domain antibodies for the conformational trapping of membrane proteins","volume":"7","author":"Zimmermann","year":"2018","journal-title":"eLife"},{"key":"10.1016\/j.canlet.2026.218699_bib95","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.16228","article-title":"NaLi-H1: a universal synthetic library of humanized nanobodies providing highly functional antibodies and intrabodies","volume":"5","author":"Moutel","year":"2016","journal-title":"eLife"},{"key":"10.1016\/j.canlet.2026.218699_bib96","doi-asserted-by":"crossref","first-page":"5506","DOI":"10.1038\/s41467-021-25777-z","article-title":"A cell-free nanobody engineering platform rapidly generates SARS-CoV-2 neutralizing nanobodies","volume":"12","author":"Chen","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2026.218699_bib97","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1021\/bi00122a025","article-title":"1H NMR assignment and secondary structure of the cell adhesion type III module of fibronectin","volume":"31","author":"Baron","year":"1992","journal-title":"Biochemistry"},{"key":"10.1016\/j.canlet.2026.218699_bib98","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2021.101403","article-title":"Thermostable designed ankyrin repeat proteins (DARPins) as building blocks for innovative drugs","volume":"298","author":"Schilling","year":"2022","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.canlet.2026.218699_bib99","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.tibtech.2017.04.007","article-title":"Affibody molecules in biotechnological and medical applications","volume":"35","author":"St\u00e5hl","year":"2017","journal-title":"Trends Biotechnol."},{"key":"10.1016\/j.canlet.2026.218699_bib100","doi-asserted-by":"crossref","first-page":"5486","DOI":"10.1073\/pnas.96.10.5486","article-title":"Solution structure and dynamics of a de novo designed three-helix bundle protein","volume":"96","author":"Walsh","year":"1999","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.canlet.2026.218699_bib101","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1016\/j.ymthe.2017.07.009","article-title":"Adnectin-Based design of chimeric antigen receptor for T cell engineering","volume":"25","author":"Han","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.canlet.2026.218699_bib102","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1089\/hum.2017.021","article-title":"Designed ankyrin repeat proteins as Her2 targeting domains in chimeric antigen receptor-engineered T cells","volume":"28","author":"Siegler","year":"2017","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.canlet.2026.218699_bib103","doi-asserted-by":"crossref","first-page":"7506","DOI":"10.1158\/1078-0432.CCR-19-1479","article-title":"Multispecific targeting with synthetic ankyrin repeat motif chimeric antigen receptors","volume":"25","author":"Balakrishnan","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2026.218699_bib104","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s40425-015-0099-4","article-title":"Designed ankyrin repeat proteins are effective targeting elements for chimeric antigen receptors","volume":"3","author":"Hammill","year":"2015","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.canlet.2026.218699_bib105","doi-asserted-by":"crossref","first-page":"4339","DOI":"10.1158\/0008-5472.CAN-05-3521","article-title":"Tumor imaging using a picomolar affinity HER2 binding affibody molecule","volume":"66","author":"Orlova","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2026.218699_bib106","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.jmb.2007.12.060","article-title":"Directed evolution to low nanomolar affinity of a tumor-targeting epidermal growth factor receptor-binding affibody molecule","volume":"376","author":"Friedman","year":"2008","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.canlet.2026.218699_bib107","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1016\/j.ymthe.2019.04.010","article-title":"Chimeric antigen receptors incorporating D domains targeting CD123 direct potent Mono- and Bi-specific antitumor activity of T cells","volume":"27","author":"Qin","year":"2019","journal-title":"Mol. Ther."},{"key":"10.1016\/j.canlet.2026.218699_bib108","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1158\/1535-7163.MCT-21-0552","article-title":"Preclinical efficacy of BCMA-directed CAR T cells incorporating a novel D domain antigen recognition domain","volume":"21","author":"Buonato","year":"2022","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.canlet.2026.218699_bib109","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1182\/bloodadvances.2022007210","article-title":"Phase 1 study of CART-ddBCMA for the treatment of subjects with relapsed and refractory multiple myeloma","volume":"7","author":"Frigault","year":"2023","journal-title":"Blood Adv."},{"key":"10.1016\/j.canlet.2026.218699_bib110","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2024-198499","article-title":"Phase 2 registrational study of anitocabtagene autoleucel for the treatment of patients with relapsed and\/or refractory multiple myeloma: preliminary results from the IMMagine-1 trial","volume":"144","author":"Freeman","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2026.218699_bib111","doi-asserted-by":"crossref","first-page":"9160","DOI":"10.1158\/0008-5472.CAN-04-0454","article-title":"Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells","volume":"64","author":"Kahlon","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2026.218699_bib112","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1038\/nbt0598-449","article-title":"Novel anti-brain tumor cytotoxins specific for cancer cells","volume":"16","author":"Debinski","year":"1998","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.canlet.2026.218699_bib116","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1182\/blood.2020008221","article-title":"CD70-specific CAR T cells have potent activity against acute myeloid leukemia without HSC toxicity","volume":"138","author":"Sauer","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2026.218699_bib117","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1002\/eji.201545749","article-title":"T cells compete by cleaving cell surface CD27 and blocking access to CD70-bearing APCs","volume":"45","author":"Burchill","year":"2015","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.canlet.2026.218699_bib118","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.exphem.2006.10.018","article-title":"Metalloprotease inhibitors block release of soluble CD27 and enhance the immune stimulatory activity of chronic lymphocytic leukemia cells","volume":"35","author":"Kato","year":"2007","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.canlet.2026.218699_bib119","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.ccell.2022.04.001","article-title":"Non-cleavable Hinge enhances avidity and expansion of CAR-T cells for acute myeloid leukemia","volume":"40","author":"Leick","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2026.218699_bib120","doi-asserted-by":"crossref","first-page":"4304","DOI":"10.1182\/blood-2010-04-278218","article-title":"T cells redirected against CD70 for the immunotherapy of CD70-positive malignancies","volume":"117","author":"Shaffer","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2026.218699_bib121","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1158\/0008-5472.CAN-21-2931","article-title":"Preclinical development and evaluation of allogeneic CAR T cells targeting CD70 for the treatment of renal cell carcinoma","volume":"82","author":"Panowski","year":"2022","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2026.218699_bib122","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1038\/nrd1197","article-title":"Therapeutic potential of venom peptides","volume":"2","author":"Lewis","year":"2003","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.canlet.2026.218699_bib123","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaw2672","article-title":"Chlorotoxin-directed CAR T cells for specific and effective targeting of glioblastoma","volume":"12","author":"Wang","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.canlet.2026.218699_bib124","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/sj.cgt.7700993","article-title":"Conversion of a tumor-binding peptide identified by phage display to a functional chimeric T cell antigen receptor","volume":"14","author":"Pameijer","year":"2007","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.canlet.2026.218699_bib125","doi-asserted-by":"crossref","first-page":"9434","DOI":"10.1021\/bi060264j","article-title":"Targeting heat shock proteins on cancer cells: selection, characterization, and cell-penetrating properties of a peptidic GRP78 ligand","volume":"45","author":"Kim","year":"2006","journal-title":"Biochemistry"},{"key":"10.1016\/j.canlet.2026.218699_bib126","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/s41467-022-28243-6","article-title":"CAR T cells redirected to cell surface GRP78 display robust anti-acute myeloid leukemia activity and do not target hematopoietic progenitor cells","volume":"13","author":"Hebbar","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2026.218699_bib127","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1158\/1541-7786.MCR-12-0300","article-title":"CLT1 targets bladder cancer through integrin \u03b15\u03b21 and CLIC3","volume":"11","author":"Knowles","year":"2013","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.canlet.2026.218699_bib128","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2024.124558","article-title":"The peptide-based bispecific CAR T cells target EGFR and tumor stroma for effective cancer therapy","volume":"663","author":"Liu","year":"2024","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.canlet.2026.218699_bib129","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adf3700","article-title":"TCR-engineered T cell therapy in solid tumors: state of the art and perspectives","volume":"9","author":"Baulu","year":"2023","journal-title":"Sci. Adv."},{"key":"10.1016\/j.canlet.2026.218699_bib130","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1172\/JCI92335","article-title":"A therapeutic T cell receptor mimic antibody targets tumor-associated PRAME peptide\/HLA-I antigens","volume":"127","author":"Chang","year":"2017","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.canlet.2026.218699_bib131","doi-asserted-by":"crossref","first-page":"5784","DOI":"10.1073\/pnas.0901425106","article-title":"Rational development of high-affinity T-cell receptor-like antibodies","volume":"106","author":"Stewart-Jones","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.canlet.2026.218699_bib132","doi-asserted-by":"crossref","first-page":"4262","DOI":"10.1182\/blood-2010-07-299248","article-title":"An anti-PR1\/HLA-A2 T-cell receptor-like antibody mediates complement-dependent cytotoxicity against acute myeloid leukemia progenitor cells","volume":"117","author":"Sergeeva","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2026.218699_bib133","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.jcyt.2016.05.001","article-title":"A novel TCR-like CAR with specificity for PR1\/HLA-A2 effectively targets myeloid leukemia in vitro when expressed in human adult peripheral blood and cord blood T cells","volume":"18","author":"Ma","year":"2016","journal-title":"Cytotherapy"},{"key":"10.1016\/j.canlet.2026.218699_bib134","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/s41551-020-00625-5","article-title":"CAR-T cells targeting a nucleophosmin neoepitope exhibit potent specific activity in mouse models of acute myeloid leukaemia","volume":"5","author":"Xie","year":"2021","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.canlet.2026.218699_bib135","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1038\/leu.2016.373","article-title":"Optimized T-cell receptor-mimic chimeric antigen receptor T cells directed toward the intracellular Wilms Tumor 1 antigen","volume":"31","author":"Rafiq","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.canlet.2026.218699_bib136","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004035","article-title":"Development of a TCR-like antibody and chimeric antigen receptor against NY-ESO-1\/HLA-A2 for cancer immunotherapy","volume":"10","author":"Liu","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.canlet.2026.218699_bib137","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/nbt1070","article-title":"Directed evolution of human T-cell receptors with picomolar affinities by phage display","volume":"23","author":"Li","year":"2005","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.canlet.2026.218699_bib138","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1038\/s41587-022-01567-w","article-title":"Facile repurposing of peptide-MHC-restricted antibodies for cancer immunotherapy","volume":"41","author":"Yang","year":"2023","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.canlet.2026.218699_bib139","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1084\/jem.187.2.265","article-title":"Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes","volume":"187","author":"J\u00e4ger","year":"1998","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.canlet.2026.218699_bib140","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1084\/jem.180.1.347","article-title":"Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes","volume":"180","author":"Kawakami","year":"1994","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.canlet.2026.218699_bib141","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/ijc.2910620118","article-title":"Identification of a novel peptide derived from the melanocyte-specific gp100 antigen as the dominant epitope recognized by an HLA-A2.1-restricted anti-melanoma CTL line","volume":"62","author":"Bakker","year":"1995","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.canlet.2026.218699_bib142","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1084\/jem.185.3.453","article-title":"Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma","volume":"185","author":"Bloom","year":"1997","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.canlet.2026.218699_bib143","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1002\/biot.201400560","article-title":"Bacterial cytoplasmic display platform retained display (ReD) identifies stable human germline antibody frameworks","volume":"10","author":"Beasley","year":"2015","journal-title":"Biotechnol. J."},{"key":"10.1016\/j.canlet.2026.218699_bib144","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1038\/s41586-023-06706-0","article-title":"Targeting of intracellular oncoproteins with peptide-centric CARs","volume":"623","author":"Yarmarkovich","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2026.218699_bib145","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.molimm.2012.06.001","article-title":"Structural analysis of B-cell epitopes in antibody:protein complexes","volume":"53","author":"Kringelum","year":"2013","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.canlet.2026.218699_bib146","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1038\/s41551-024-01258-8","article-title":"Targeting overexpressed antigens in glioblastoma via CAR T cells with computationally designed high-affinity protein binders","volume":"8","author":"Xia","year":"2024","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.canlet.2026.218699_bib147","series-title":"Sequence and Structural Determinants of Efficacious De Novo Chimeric Antigen Receptors","author":"Chow","year":"2025"},{"key":"10.1016\/j.canlet.2026.218699_bib148","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1158\/1535-7163.MCT-21-0115","article-title":"T-Cell receptor mimic antibodies for cancer immunotherapy","volume":"20","author":"Duan","year":"2021","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.canlet.2026.218699_bib149","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1126\/science.adv0185","article-title":"Design of high-specificity binders for peptide-MHC-I complexes","volume":"389","author":"Liu","year":"2025","journal-title":"Science"},{"key":"10.1016\/j.canlet.2026.218699_bib150","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.str.2023.11.011","article-title":"Accurate modeling of peptide-MHC structures with AlphaFold","volume":"32","author":"Mikhaylov","year":"2024","journal-title":"Structure"},{"key":"10.1016\/j.canlet.2026.218699_bib152","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1038\/s41467-023-38328-5","article-title":"Improving de novo protein binder design with deep learning","volume":"14","author":"Bennett","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2026.218699_bib153","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1016\/j.str.2025.08.007","article-title":"Code to complex: ai-driven de novo binder design","volume":"33","author":"Fox","year":"2025","journal-title":"Structure"},{"key":"10.1016\/j.canlet.2026.218699_bib154","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1038\/s41586-026-10328-7","article-title":"The past, present and future of de novo protein design","volume":"652","author":"Yang","year":"2026","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2026.218699_bib155","doi-asserted-by":"crossref","first-page":"e4726","DOI":"10.1002\/pro.4726","article-title":"Computational design of N-linked glycans for high throughput epitope profiling","volume":"32","author":"Greisen","year":"2023","journal-title":"Protein Sci."},{"key":"10.1016\/j.canlet.2026.218699_bib156","doi-asserted-by":"crossref","first-page":"4968","DOI":"10.1016\/j.ymthe.2025.07.044","article-title":"Computational structural optimization enhances IL13R\u03b12 - B7-H3 tandem CAR T cells to overcome antigen-heterogeneity-mediated tumor escape","volume":"33","author":"Meehl","year":"2025","journal-title":"Mol. Ther."},{"key":"10.1016\/j.canlet.2026.218699_bib157","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.ymthe.2024.11.028","article-title":"ARI0003: Co-transduced CD19\/BCMA dual-targeting CAR-T cells for the treatment of Non-Hodgkin lymphoma","volume":"33","author":"Bachiller","year":"2025","journal-title":"Mol. Ther."},{"key":"10.1016\/j.canlet.2026.218699_bib158","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s40364-020-00192-6","article-title":"Characterization of novel dual tandem CD19\/BCMA chimeric antigen receptor T cells to potentially treat multiple myeloma","volume":"8","author":"Kang","year":"2020","journal-title":"Biomark. Res."},{"key":"10.1016\/j.canlet.2026.218699_bib159","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1080\/07357907.2025.2548603","article-title":"Tandem dual CAR-T cells targeting HER2 and mesothelin enhance Anti-Tumor effects in pancreatic cancer","volume":"43","author":"Jiang","year":"2025","journal-title":"Cancer Invest."},{"key":"10.1016\/j.canlet.2026.218699_bib160","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.ymthe.2021.08.033","article-title":"A novel and efficient tandem CD19- and CD22-directed CAR for B cell ALL","volume":"30","author":"Zanetti","year":"2022","journal-title":"Mol. Ther."},{"key":"10.1016\/j.canlet.2026.218699_bib161","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/ejh.14104","article-title":"Tandem bispecific CD123\/CLL-1 CAR-T cells exhibit specific cytolytic effector functions against human acute myeloid leukaemia","volume":"112","author":"Wang","year":"2024","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.canlet.2026.218699_bib162","doi-asserted-by":"crossref","first-page":"5229","DOI":"10.1038\/s41467-026-72040-4","article-title":"Demethylation-primed tandem CD19\/CD20 CAR T cells in relapsed\/refractory B-cell lymphoma: a phase I\/II trial","volume":"17","author":"Wang","year":"2026","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2026.218699_bib163","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1038\/mt.2013.185","article-title":"Combinational targeting offsets antigen escape and enhances effector functions of adoptively transferred T cells in glioblastoma","volume":"21","author":"Hegde","year":"2013","journal-title":"Mol. Ther."},{"key":"10.1016\/j.canlet.2026.218699_bib164","doi-asserted-by":"crossref","first-page":"7622","DOI":"10.7150\/thno.43991","article-title":"Tandem CAR-T cells targeting CD70 and B7-H3 exhibit potent preclinical activity against multiple solid tumors","volume":"10","author":"Yang","year":"2020","journal-title":"Theranostics"},{"key":"10.1016\/j.canlet.2026.218699_bib165","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2025.105872","article-title":"Tandem CD19\/CD22 CAR T-cells as potential therapy for children and young adults with high-risk r\/r B-ALL","volume":"118","author":"Gonz\u00e1lez-Mart\u00ednez","year":"2025","journal-title":"EBioMedicine"},{"key":"10.1016\/j.canlet.2026.218699_bib166","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1038\/s41591-020-1081-3","article-title":"Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial","volume":"26","author":"Shah","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2026.218699_bib167","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1038\/s41591-021-01436-0","article-title":"CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial","volume":"27","author":"Spiegel","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2026.218699_bib168","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1038\/s41467-020-16160-5","article-title":"Systematically optimized BCMA\/CS1 bispecific CAR-T cells robustly control heterogeneous multiple myeloma","volume":"11","author":"Zah","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2026.218699_bib169","article-title":"Peptide-scFv antigen recognition domains effectively confer CAR T cell multiantigen specificity","volume":"5","author":"Zoine","year":"2024","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.canlet.2026.218699_bib170","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.omto.2018.10.006","article-title":"Preclinical development of bivalent chimeric antigen receptors targeting both CD19 and CD22","volume":"11","author":"Qin","year":"2018","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.canlet.2026.218699_bib171","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1093\/procel\/pwae034","article-title":"A novel loop-structure-based bispecific CAR that targets CD19 and CD22 with enhanced therapeutic efficacy against B-cell malignancies","volume":"16","author":"Zhao","year":"2025","journal-title":"Protein Cell"},{"key":"10.1016\/j.canlet.2026.218699_bib172","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/nbt.2459","article-title":"Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells","volume":"31","author":"Kloss","year":"2013","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.canlet.2026.218699_bib173","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1016\/j.cell.2022.03.041","article-title":"Enhanced safety and efficacy of protease-regulated CAR-T cell receptors","volume":"185","author":"Labanieh","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2026.218699_bib174","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.chembiol.2005.10.017","article-title":"Rapamycin analogs with differential binding specificity permit orthogonal control of protein activity","volume":"13","author":"Bayle","year":"2006","journal-title":"Chem. Biol."},{"key":"10.1016\/j.canlet.2026.218699_bib175","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1126\/science.273.5272.239","article-title":"Structure of the FKBP12-rapamycin complex interacting with the binding domain of human FRAP","volume":"273","author":"Choi","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.canlet.2026.218699_bib176","doi-asserted-by":"crossref","first-page":"7825","DOI":"10.1073\/pnas.94.15.7825","article-title":"Inducible gene expression and protein translocation using nontoxic ligands identified by a mammalian three-hybrid screen","volume":"94","author":"Liberles","year":"1997","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.canlet.2026.218699_bib177","doi-asserted-by":"crossref","DOI":"10.1126\/science.aab4077","article-title":"Remote control of therapeutic T cells through a small molecule-gated chimeric receptor","volume":"350","author":"Wu","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.canlet.2026.218699_bib178","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1016\/j.cell.2018.03.038","article-title":"Universal chimeric antigen receptors for multiplexed and logical control of T cell responses","volume":"173","author":"Cho","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2026.218699_bib179","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/s41586-023-05778-2","article-title":"Co-opting signalling molecules enables logic-gated control of CAR T cells","volume":"615","author":"Tousley","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2026.218699_bib180","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1126\/science.aba6527","article-title":"Designed protein logic to target cells with precise combinations of surface antigens","volume":"369","author":"Lajoie","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.canlet.2026.218699_bib181","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1016\/S0140-6736(25)00860-8","article-title":"Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician's choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial","volume":"405","author":"Qi","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.canlet.2026.218699_bib182","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaf8621","article-title":"Immunotherapy of non-hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells","volume":"8","author":"Turtle","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.canlet.2026.218699_bib183","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/nm.3838","article-title":"4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors","volume":"21","author":"Long","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2026.218699_bib184","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.8504","article-title":"Orvacabtagene autoleucel (Orva-cel), a B-cell maturation antigen (BCMA)-directed CAR T cell therapy for patients (pts) with relapsed\/refractory multiple myeloma (RRMM): update of the phase 1\/2 EVOLVE study (NCT03430011)","volume":"38","author":"Mailankody","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2026.218699_bib185","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1038\/s41375-025-02518-5","article-title":"Phase 1 clinical trial of B-Cell maturation antigen (BCMA) NEX-T\u00ae chimeric antigen receptor (CAR) T cell therapy CC-98633\/BMS-986354 in participants with triple-class exposed multiple myeloma","volume":"39","author":"Ravi","year":"2025","journal-title":"Leukemia"},{"key":"10.1016\/j.canlet.2026.218699_bib186","doi-asserted-by":"crossref","DOI":"10.1126\/science.aba1786","article-title":"Transient rest restores functionality in exhausted CAR-T cells through epigenetic remodeling","volume":"372","author":"Weber","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.canlet.2026.218699_bib187","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1126\/science.adv0422","article-title":"De novo-designed pMHC binders facilitate T cell-mediated cytotoxicity toward cancer cells","volume":"389","author":"Johansen","year":"2025","journal-title":"Science"},{"key":"10.1016\/j.canlet.2026.218699_bib188","series-title":"Validation and Analysis of 12,000 AI-driven CAR-T Designs in the Bits to Binders Competitions","author":"Kosonocky","year":"2026"}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383526004635?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383526004635?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T21:32:47Z","timestamp":1785965567000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383526004635"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":195,"alternative-id":["S0304383526004635"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2026.218699","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Multi-dimensional orchestration of binders for improved CAR-T immunotherapy","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2026.218699","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"218699"}}